Andrea L. Wellington

Array ( [id] => 16328443 [patent_doc_number] => 20200299409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/790656 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 222543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16790656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328442 [patent_doc_number] => 20200299408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/790616 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 222546 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16790616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16377507 [patent_doc_number] => 20200326349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => Isolating Cells Expressing Secreted Proteins [patent_app_type] => utility [patent_app_number] => 16/788961 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993449 [patent_doc_number] => 20200172595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/789057 [patent_app_country] => US [patent_app_date] => 2020-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012819 [patent_doc_number] => 20200181252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/784621 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302067 [patent_doc_number] => 11623958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Single chain variable fragment CD3 binding proteins [patent_app_type] => utility [patent_app_number] => 16/773806 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 21838 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 543 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376382 [patent_doc_number] => 20200325224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => ANTIBODIES BINDING TO HUMAN AND CYNOMOLGUS CD3 EPSILON [patent_app_type] => utility [patent_app_number] => 16/751046 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328419 [patent_doc_number] => 20200299385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTIBODIES BINDING TO HUMAN AND CYNOMOLGUS CD3 EPSILON [patent_app_type] => utility [patent_app_number] => 16/751062 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264165 [patent_doc_number] => 12435141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Antigen binding constructs to CD8 [patent_app_type] => utility [patent_app_number] => 16/745064 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 44 [patent_no_of_words] => 18374 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233224 [patent_doc_number] => 11597773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => CD6 antibody for treatment of T-cell mediated diseases or disorders [patent_app_type] => utility [patent_app_number] => 16/743278 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 45 [patent_no_of_words] => 14051 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413159 [patent_doc_number] => 11667692 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => T cell receptors recognizing HLA-CW8 restricted mutated KRAS [patent_app_type] => utility [patent_app_number] => 16/739310 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18382 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16739310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832164 [patent_doc_number] => 11008405 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies to MASP-2 [patent_app_type] => utility [patent_app_number] => 16/736626 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17306 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111653 [patent_doc_number] => 20200207849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/736337 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 251 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866273 [patent_doc_number] => 20200140540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/733845 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076517 [patent_doc_number] => 11945867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody [patent_app_type] => utility [patent_app_number] => 17/287307 [patent_app_country] => US [patent_app_date] => 2019-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8449 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15740637 [patent_doc_number] => 20200109206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => SELECTIVE ELIMINATION OF EROSIVE CELLS [patent_app_type] => utility [patent_app_number] => 16/718935 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844947 [patent_doc_number] => 11434300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Methods and antibody compositions for tumor treatment [patent_app_type] => utility [patent_app_number] => 16/716980 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 42 [patent_no_of_words] => 38484 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16716980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681769 [patent_doc_number] => 20200095548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD [patent_app_type] => utility [patent_app_number] => 16/710287 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28111 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768883 [patent_doc_number] => 20200115459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/710988 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711245 [patent_doc_number] => 20200102388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/706377 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16706377 [rel_patent_id] =>[rel_patent_doc_number] =>)